Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial

BACKGROUND: Pyoderma gangrenosum (PG) is a chronic ulcerating skin condition that often occurs in association with inflammatory bowel disease. There have been a number of reports of PG responding to infliximab, a monoclonal antibody against tumour necrosis factor α. AIM: In the first randomised plac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Brooklyn, T N, Dunnill, M G S, Shetty, A, Bowden, J J, Williams, J D L, Griffiths, C E M, Forbes, A, Greenwood, R, Probert, C S
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2006
Assuntos:
Inflammatory Bowel Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856164/
https://ncbi.nlm.nih.gov/pubmed/16188920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2005.074815
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados